Copertina

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Nathaniel M. Schuster, Mark S. Wallace, Thomas D. Marcotte, Dawn C. Buse, Euyhyun Lee, Lin Liu, Michelle Sexton
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial
di: Ghader Mohammadnezhad, et al.
Pubblicazione: (2024)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
di: Muneto Tatsumoto, et al.
Pubblicazione: (2024)

A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study
di: Jeffrey D. Sharon, et al.
Pubblicazione: (2024)

Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
di: Emmanuelle A. D. Schindler, et al.
Pubblicazione: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
di: Koichi Ikeda, et al.
Pubblicazione: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
di: Larry Charleston, et al.
Pubblicazione: (2026)

Partial rebreathing is not effective for early treatment of migraine with aura attacks: Results of a double‐blind, randomized, controlled trial ( PAREMA1 )
di: Charly Gaul, et al.
Pubblicazione: (2025)

Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study
di: Dawn C. Buse, et al.
Pubblicazione: (2026)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
di: Rikki Mangrum, et al.
Pubblicazione: (2024)

Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial
di: Serena Laura Orr, et al.
Pubblicazione: (2024)

Prevalence and burden of migraine in the United States: A systematic review
di: Fred Cohen, et al.
Pubblicazione: (2024)

Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trials
di: Richard Bertz, et al.
Pubblicazione: (2025)

Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi‐country results from the CaMEO‐I study
di: Dawn C. Buse, et al.
Pubblicazione: (2024)

Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo‐controlled study in healthy adults
di: Rajinder Bhardwaj, et al.
Pubblicazione: (2024)

Unmet treatment needs in migraine: Results of the OVERCOME (US) study
di: Susan Hutchinson, et al.
Pubblicazione: (2026)

What a long strange trip it's been: Reflections on serial snapshots of migraine prevalence and burden in the United States
di: Fred Cohen, et al.
Pubblicazione: (2025)

Behavioral interventions for migraine prevention: A systematic review and meta‐analysis
di: Jonathan R. Treadwell, et al.
Pubblicazione: (2025)

Challenges and opportunities for estimating and assessing migraine prevalence, incidence and impact across study populations and methodologies: Bridging global and United States findings
di: Fred Cohen, et al.
Pubblicazione: (2024)

A post hoc analysis of migraine‐associated symptoms from the phase 3 randomized, double‐blind, sham‐controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine ( TEAM) study
di: Gregory A. Panza, et al.
Pubblicazione: (2024)

Integrating gepants into clinical practice for the acute treatment of migraine
di: Richard B. Lipton, et al.
Pubblicazione: (2026)

Mechanisms for mindfulness in migraine: Does catastrophizing matter?
di: Rebecca Erwin Wells, et al.
Pubblicazione: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
di: Anna Gryglas‐Dworak, et al.
Pubblicazione: (2024)

Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study
di: Dawn C. Buse, et al.
Pubblicazione: (2025)

Correction to “Smartphone‐delivered progressive muscle relaxation for the treatment of migraine in primary care: A randomized controlled trial”
Pubblicazione: (2025)

The PATCH trial: 5% lidocaine‐medicated plaster for trigeminal neuralgia—Results of a multicentric, enriched enrollment, randomized withdrawal, double‐blind, vehicle‐controlled, parallel‐group study
di: Chunmei Zhao, et al.
Pubblicazione: (2024)

The impact of headache intensity on speech in participants with migraine and acute post‐traumatic headache
di: Dani C. Smith, et al.
Pubblicazione: (2024)

Novel optimization of multi‐mechanistic approaches for the acute treatment of a migraine attack: A review
di: Stephen Silberstein, et al.
Pubblicazione: (2026)

IV dexamethasone as adjuvant therapy to metoclopramide for acute posttraumatic headache in the ED : A randomized controlled trial
di: Kareem Joudi, et al.
Pubblicazione: (2026)

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
di: Stephen D. Silberstein, et al.
Pubblicazione: (2024)

A retrospective analysis of the use of candesartan for migraine prevention in adolescents
di: Irene Patniyot, et al.
Pubblicazione: (2024)

Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon
di: Stephanie J. Nahas, et al.
Pubblicazione: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
di: Graham A. McLeod, et al.
Pubblicazione: (2025)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
di: Geneviève Tourigny‐Ruel, et al.
Pubblicazione: (2026)

Differential impact of migraine on severe maternal morbidity and postpartum readmissions: Insights from a national cohort study
di: Michelle T. Tram, et al.
Pubblicazione: (2026)

Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study
di: Devin Teichrow, et al.
Pubblicazione: (2026)

Response to: Disagreement with Categorization of Clinical Trials included in Treadwell et al. Systematic Review and Meta‐Analysis
di: Jonathan R. Treadwell, et al.
Pubblicazione: (2025)

Engagement and predictors of use of a smartphone app for migraine self‐management: A secondary analysis of the EMMA trial
di: Stefanie Lysk, et al.
Pubblicazione: (2025)

2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
di: Jennifer Robblee, et al.
Pubblicazione: (2025)

Exploring the impact of acute SARS‐CoV‐2 infection on headache pattern in patients with migraine: A novel Bayesian analysis
di: Jiunn‐Tyng Yeh, et al.
Pubblicazione: (2025)